|
PTEN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.062200327695E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.49660003571029E-09 |
| Normal-vs-Stage2 |
8.48060000000483E-05 |
| Normal-vs-Stage3 |
5.31709998252694E-09 |
| Normal-vs-Stage4 |
7.36609999663074E-08 |
| Stage1-vs-Stage2 |
8.695200E-01 |
| Stage1-vs-Stage3 |
2.881000E-01 |
| Stage1-vs-Stage4 |
2.442000E-01 |
| Stage2-vs-Stage3 |
3.874600E-01 |
| Stage2-vs-Stage4 |
2.898200E-01 |
| Stage3-vs-Stage4 |
7.356400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.12979958721837E-10 |
| Normal-vs-AfricanAmerican |
8.756000E-03 |
| Normal-vs-Asian |
1.11670000024766E-07 |
| Caucasian-vs-AfricanAmerican |
1.484980E-01 |
| Caucasian-vs-Asian |
5.261800E-01 |
| AfricanAmerican-vs-Asian |
6.438300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.88780000520694E-08 |
| Normal-vs-Female |
4.46359949002328E-10 |
| Male-vs-Female |
7.215800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.0723999995016E-07 |
| Normal-vs-Age(41-60Yrs) |
4.8804960073312E-11 |
| Normal-vs-Age(61-80Yrs) |
1.66129999978892E-07 |
| Normal-vs-Age(81-100Yrs) |
1.590340E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.759600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.439400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.857800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.223800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.325200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.090800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.707580E-01 |
| Classical-VS-Follicular |
5.553000E-01 |
| Classical-VS-Other |
3.636200E-01 |
| Classical-VS-Normal |
1.7453000156209E-09 |
| Tall-VS-Follicular |
1.468420E-01 |
| Tall-VS-Other |
8.401200E-01 |
| Tall-VS-Normal |
5.91060000054711E-07 |
| Follicular-VS-Other |
3.472200E-01 |
| Follicular-VS-Normal |
3.97460000000072E-05 |
| Other-VS-Normal |
7.364300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.97870008845325E-10 |
| Normal-vs-N1 |
2.93549995422637E-09 |
| N0-vs-N1 |
1.692790E-01 |
|
|
